Identification of Putative Binding Sites of P‐glycoprotein Based on its Homology Model

A homology model of P‐glycoprotein based on the crystal structure of the multidrug transporter Sav1866 is developed, incorporated into a membrane environment, and optimized. The resulting model is analyzed in relation to the functional state and potential binding sites. The comparison of modeled distances to distances reported in experimental studies between particular residues suggests that the model corresponds most closely to the first ATP hydrolysis step of the protein transport cycle. Comparison to the protein 3D structure confirms this suggestion. Using SiteID and Site Finder programs three membrane related binding regions are identified: a region at the interface between the membrane and cytosol and two regions located in the transmembrane domains. The regions contain binding pockets of different size, orientation, and amino acids. A binding pocket located inside the membrane cavity is also identified. The pockets are analyzed in relation to amino acids shown experimentally to influence the protein function. The results suggest that the protein has multiple binding sites and may bind and/or release substrates in multiple pathways.

[1]  Amos Bairoch,et al.  ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins , 2006, Nucleic Acids Res..

[2]  M. R. Lugo,et al.  Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. , 2005, Biochemistry.

[3]  A. Lesk,et al.  The relation between the divergence of sequence and structure in proteins. , 1986, The EMBO journal.

[4]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[5]  T. Kwan,et al.  Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains. , 1998, Biochemistry.

[6]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[7]  D. Clarke,et al.  Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[9]  K. Ueda,et al.  Amino acid substitutions in the first transmembrane domain (TM1) of P‐glycoprotein that alter substrate specificity , 1997, FEBS letters.

[10]  V. Ling,et al.  Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. , 1997, European journal of biochemistry.

[11]  I. Ojima,et al.  The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel. , 2001, Molecular pharmacology.

[12]  D. Clarke,et al.  Disulfide Cross-linking Analysis Shows That Transmembrane Segments 5 and 8 of Human P-glycoprotein Are Close Together on the Cytoplasmic Side of the Membrane* , 2004, Journal of Biological Chemistry.

[13]  D. Clarke,et al.  Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.

[14]  Christoph Globisch,et al.  Structure-function relationships of multidrug resistance P-glycoprotein. , 2004, Journal of medicinal chemistry.

[15]  D. J. Gruol,et al.  Identification of P-glycoprotein Mutations Causing a Loss of Steroid Recognition and Transport* , 1999, The Journal of Biological Chemistry.

[16]  D. Clarke,et al.  Methanethiosulfonate Derivatives of Rhodamine and Verapamil Activate Human P-glycoprotein at Different Sites* , 2003, Journal of Biological Chemistry.

[17]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[18]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[19]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[20]  D. Clarke,et al.  Val133 and Cys137 in Transmembrane Segment 2 Are Close to Arg935 and Gly939 in Transmembrane Segment 11 of Human P-glycoprotein* , 2004, Journal of Biological Chemistry.

[21]  K. Linton,et al.  Structure and function of ABC transporters: the ATP switch provides flexible control , 2007, Pflügers Archiv - European Journal of Physiology.

[22]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[23]  K. Linton,et al.  The Topography of Transmembrane Segment Six Is Altered during the Catalytic Cycle of P-glycoprotein* , 2004, Journal of Biological Chemistry.

[24]  C. Higgins,et al.  Three-dimensional Structure of P-glycoprotein , 2005, Journal of Biological Chemistry.

[25]  D. Clarke,et al.  Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. , 1994, Biochemistry.

[26]  K. Locher,et al.  Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP‐PNP , 2007, FEBS letters.

[27]  K. Linton,et al.  An atomic detail model for the human ATP binding cassette transporter P‐glycoprotein derived from disulphide cross‐ linking and homology modeling , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  D. Clarke,et al.  Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.

[29]  Alexander D. MacKerell,et al.  Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..

[30]  Stephan Kopp,et al.  Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. , 2002, Molecular pharmacology.

[31]  D. Valle,et al.  Characterization and Analysis of Conserved Motifs in a Peroxisomal ATP-binding Cassette Transporter (*) , 1996, The Journal of Biological Chemistry.

[32]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .

[33]  M S Sansom,et al.  An alamethicin channel in a lipid bilayer: molecular dynamics simulations. , 1999, Biophysical journal.

[34]  C. Higgins,et al.  Communication between multiple drug binding sites on P-glycoprotein. , 2000, Molecular pharmacology.

[35]  Chow H Lee.  Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). , 2004, Current medicinal chemistry. Anti-cancer agents.

[36]  Rachelle Gaudet,et al.  Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing , 2001, The EMBO journal.

[37]  V. Ling,et al.  Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. , 2001, European journal of biochemistry.

[38]  T. Kwan,et al.  Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning. , 1996, Biochemistry.

[39]  D. Clarke,et al.  Defining the Drug-binding Site in the Human Multidrug Resistance P-glycoprotein Using a Methanethiosulfonate Analog of Verapamil, MTS-verapamil* , 2001, The Journal of Biological Chemistry.

[40]  H. Kroemer,et al.  The ABC Transporters MDR1 and MRP2: Multiple Functions in Disposition of Xenobiotics and Drug Resistance , 2004, Drug metabolism reviews.

[41]  D. Tieleman,et al.  P‐glycoprotein models of the apo and ATP‐bound states based on homology with Sav1866 and MalK , 2007, FEBS letters.

[42]  M. Borgnia,et al.  Competition of Hydrophobic Peptides, Cytotoxic Drugs, and Chemosensitizers on a Common P-glycoprotein Pharmacophore as Revealed by Its ATPase Activity (*) , 1996, The Journal of Biological Chemistry.

[43]  Y. Shao,et al.  Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. , 1996, Biochimica et biophysica acta.

[44]  O. Berger,et al.  Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. , 1997, Biophysical journal.

[45]  K. Linton,et al.  Evidence for a Sav1866‐like architecture for the human multidrug transporter P‐glycoprotein , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  M. Kuehne,et al.  Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein. , 2002, Molecular pharmacology.

[47]  S. Kane,et al.  Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. , 1997, Biochemistry.

[48]  M S Sansom,et al.  Alamethicin helices in a bilayer and in solution: molecular dynamics simulations. , 1999, Biophysical journal.

[49]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[50]  D. Clarke,et al.  Determining the Dimensions of the Drug-binding Domain of Human P-glycoprotein Using Thiol Cross-linking Compounds as Molecular Rulers* , 2001, The Journal of Biological Chemistry.

[51]  Berk Hess,et al.  GROMACS 3.0: a package for molecular simulation and trajectory analysis , 2001 .

[52]  D. Clarke,et al.  Cross-linking of Human Multidrug Resistance P-glycoprotein by the Substrate, Tris-(2-maleimidoethyl)amine, Is Altered by ATP Hydrolysis , 2001, The Journal of Biological Chemistry.

[53]  I. Pastan,et al.  Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system. , 1998, Molecular pharmacology.

[54]  D. Clarke,et al.  Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. , 2006, The Biochemical journal.

[55]  Christian Kandt,et al.  Membrane protein simulations with a united-atom lipid and all-atom protein model: lipid–protein interactions, side chain transfer free energies and model proteins , 2006, Journal of physics. Condensed matter : an Institute of Physics journal.

[56]  A. Safa,et al.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. , 2004, Current medicinal chemistry. Anti-cancer agents.

[57]  G. Szakács,et al.  Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.

[58]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[59]  P. Melera,et al.  Transmembrane domain (TM) 9 represents a novel site in P-glycoprotein that affects drug resistance and cooperates with TM6 to mediate [125I]iodoarylazidoprazosin labeling. , 2001, Molecular pharmacology.

[60]  D. Clarke,et al.  ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. , 2005, Biochemistry.

[61]  Stephan Kopp,et al.  P-Glycoprotein Substrate Binding Domains Are Located at the Transmembrane Domain/Transmembrane Domain Interfaces: A Combined Photoaffinity Labeling-Protein Homology Modeling Approach , 2005, Molecular Pharmacology.